|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005768,
umls-concept:C0014912,
umls-concept:C0023607,
umls-concept:C0030705,
umls-concept:C0033371,
umls-concept:C0038148,
umls-concept:C0039286,
umls-concept:C0439810,
umls-concept:C0441889,
umls-concept:C0443483,
umls-concept:C0733758,
umls-concept:C1280500,
umls-concept:C1418938,
umls-concept:C1704272,
umls-concept:C1880497,
umls-concept:C1996904
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1983-11-23
|
|
pubmed:abstractText |
Treatment of 9 patients with benign prostatic hyperplasia with 20 mg tamoxifen daily for 6 weeks resulted in a significant increase of LH (211%), FSH (215%), E2 (231%), total T (157%), free T (148%) and total DHT (148%) levels in blood. The increase of plasma free DHT (152%) levels was not significant and PRL concentrations in serum were unchanged during treatment. Comparison of the increases between total T and free T, total T and total DHT as well as free T and free DHT failed to reveal any significant differences. These results imply (1) a marked anti-oestrogenic effect of tamoxifen at the level of hypothalamo-hypophysial axis (2) no effect at the hepatic oestrogen receptor sites indicated by unchanged SHBG-bound T and DHT in plasma and (3) no significant inhibitory effect of tamoxifen on 5 alpha-reductase activity concluded from the T/DHT ratio in peripheral circulation. In view of these findings tamoxifen appears to be unsuitable for therapy of benign prostatic hyperplasia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0232-7384
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
21-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:6193975-Dihydrotestosterone,
pubmed-meshheading:6193975-Estradiol,
pubmed-meshheading:6193975-Follicle Stimulating Hormone,
pubmed-meshheading:6193975-Hormones,
pubmed-meshheading:6193975-Humans,
pubmed-meshheading:6193975-Luteinizing Hormone,
pubmed-meshheading:6193975-Male,
pubmed-meshheading:6193975-Prolactin,
pubmed-meshheading:6193975-Prostatic Hyperplasia,
pubmed-meshheading:6193975-Tamoxifen,
pubmed-meshheading:6193975-Testosterone,
pubmed-meshheading:6193975-Time Factors
|
|
pubmed:year |
1983
|
|
pubmed:articleTitle |
Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia.
|
|
pubmed:publicationType |
Journal Article
|
